AMH levels at central precocious puberty and premature thelarche: is it a parameter?

J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1351-6. doi: 10.1515/jpem-2014-0521.

Abstract

Background: The possible difference of antimüllerian hormone (AMH) levels at central precocious puberty (CPP) and premature thelarche (PT) has not been properly evaluated.

Objective/hypothesis: By evaluating AMH levels in girls with diagnosed CPP and PT, we aim to show the change of AMH levels at the pubertal onset.

Subjects: Sixty-five girls who have breast development before the age of 8 years and 25 healthy girls were enrolled in the study.

Methods: The subjects were divided into two groups as CPP and PT, according to results of GnRH test. AMH levels were determined in the two groups.

Results: The mean AMH levels of the CPP group were significantly lower than those in the PT group (13.57±9.85 pmol/L and 58.42±12.78 pmol/L, respectively, p=0.022).

Conclusion: These results suggest that the AMH levels decrease in the duration of the hypothalamus-pituitary-ovarian axis activation. We thought that AMH might/may be a marker for distinguishing between CPP and PT.

MeSH terms

  • Anti-Mullerian Hormone / blood*
  • Biomarkers / blood
  • Breast / growth & development
  • Child
  • Child, Preschool
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Luteinizing Hormone / blood
  • Puberty, Precocious / blood*

Substances

  • Biomarkers
  • Anti-Mullerian Hormone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone